Lyka Labs Limited (NSE:LYKALABS)
73.62
+1.44 (2.00%)
Aug 21, 2026, 3:14 PM IST
Lyka Labs Revenue
Lyka Labs had revenue of 423.09M INR in the quarter ending June 30, 2026, with 28.11% growth. This brings the company's revenue in the last twelve months to 1.34B, down -2.69% year-over-year. In the fiscal year ending March 31, 2026, Lyka Labs had annual revenue of 1.25B, down -7.27%.
Revenue (ttm)
1.34B
Revenue Growth
-2.69%
P/S Ratio
1.96
Revenue / Employee
2.07M
Employees
648
Market Cap
2.63B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 1.25B | -97.91M | -7.27% |
| Mar 31, 2025 | 1.35B | 284.33M | 26.78% |
| Mar 31, 2024 | 1.06B | 167.66M | 18.75% |
| Mar 31, 2023 | 894.17M | -950.50M | -51.53% |
| Mar 31, 2022 | 1.84B | 1.16B | 169.25% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Biocon | 173.21B |
| Dishman Carbogen Amcis | 29.01B |
| Anthem Biosciences | 20.07B |
| OneSource Specialty Pharma | 15.43B |
| Concord Biotech | 11.08B |
| Blue Jet Healthcare | 8.86B |
| Supriya Lifescience | 8.73B |
| Panacea Biotec | 6.73B |
Lyka Labs News
- 1 year ago - Lyka Labs shares fall 3% as Q1 net profit falls 20% YoY; Check earnings - Business Upturn
- 1 year ago - Lyka Labs secures patent for Pregabalin Gel 8% to treat diabetic neuropathic pain - Business Upturn